Gilead Sciences Inc. (NASDAQ:GILD)‘s stock had its “outperform” rating reaffirmed by stock analysts at Cowen and Company in a research note issued on Monday. They currently have a $120.00 price objective on the biopharmaceutical company’s stock. Cowen and Company’s price objective would suggest a potential upside of 63.47% from the stock’s current price.

A number of other equities analysts have also commented on GILD. Piper Jaffray Cos. set a $108.00 price target on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Sunday, August 21st. Jefferies Group reissued a “hold” rating and issued a $96.00 price target on shares of Gilead Sciences in a report on Wednesday, June 29th. RBC Capital Markets reissued an “outperform” rating and issued a $105.00 price target (down previously from $120.00) on shares of Gilead Sciences in a report on Tuesday, July 26th. Leerink Swann reissued an “outperform” rating and issued a $127.00 price target on shares of Gilead Sciences in a report on Wednesday, June 29th. Finally, Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a report on Monday, September 26th. Ten research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $102.78.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Gilead Sciences (NASDAQ:GILD) opened at 73.41 on Monday. The company has a 50-day moving average of $77.59 and a 200 day moving average of $84.05. The firm has a market cap of $96.88 billion, a price-to-earnings ratio of 6.44 and a beta of 1.10. Gilead Sciences has a 12-month low of $72.21 and a 12-month high of $111.11.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 EPS for the quarter, topping the Zacks’ consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analyst estimates of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The business’s revenue for the quarter was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $3.15 EPS. Equities analysts expect that Gilead Sciences will post $11.76 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 29th. Investors of record on Friday, September 16th were given a dividend of $0.47 per share. The ex-dividend date of this dividend was Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.56%. Gilead Sciences’s dividend payout ratio (DPR) is 16.56%.

In other Gilead Sciences news, insider John C. Martin sold 100,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $80.50, for a total transaction of $8,050,000.00. Following the transaction, the insider now owns 4,119,727 shares of the company’s stock, valued at $331,638,023.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of Gilead Sciences stock in a transaction that occurred on Monday, August 1st. The shares were sold at an average price of $79.81, for a total transaction of $159,620.00. Following the transaction, the executive vice president now directly owns 64,122 shares in the company, valued at approximately $5,117,576.82. The disclosure for this sale can be found here. Corporate insiders own 1.40% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Exane Derivatives increased its position in shares of Gilead Sciences by 59.0% in the first quarter. Exane Derivatives now owns 17,270 shares of the biopharmaceutical company’s stock valued at $1,586,000 after buying an additional 6,405 shares in the last quarter. Addenda Capital Inc. increased its position in shares of Gilead Sciences by 0.3% in the first quarter. Addenda Capital Inc. now owns 127,960 shares of the biopharmaceutical company’s stock valued at $11,755,000 after buying an additional 378 shares in the last quarter. Bowling Portfolio Management LLC increased its position in shares of Gilead Sciences by 49.7% in the first quarter. Bowling Portfolio Management LLC now owns 108,400 shares of the biopharmaceutical company’s stock valued at $9,958,000 after buying an additional 36,005 shares in the last quarter. Torray LLC increased its position in shares of Gilead Sciences by 31.7% in the first quarter. Torray LLC now owns 453,420 shares of the biopharmaceutical company’s stock valued at $41,651,000 after buying an additional 109,025 shares in the last quarter. Finally, Carderock Capital Management Inc. increased its position in shares of Gilead Sciences by 5.6% in the first quarter. Carderock Capital Management Inc. now owns 14,018 shares of the biopharmaceutical company’s stock valued at $1,288,000 after buying an additional 748 shares in the last quarter. 78.00% of the stock is currently owned by institutional investors and hedge funds.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.